Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance.
J Antimicrob Chemother
; 72(10): 2704-2707, 2017 10 01.
Article
em En
| MEDLINE
| ID: mdl-29091185
ABSTRACT
Background:
Like other streptococci, Streptococcus agalactiae typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in 2 of 1125 isolates collected in the BSAC Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterized.Methods:
Identifications were by latex agglutination, MICs by BSAC agar dilution and sequencing by Illumina methodology.Results:
Gentamicin MICs were >1024 mg/L versus a species mode of 8 mg/L; both isolates also were unusually ciprofloxacin resistant with MICs of 64 mg/L versus a species mode of 1 mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs globally. Both had aac(6')-aph(2â³), carried by different transposons, explaining their gentamicin resistance, and had gyrA[81S-L];parC[79S-Y], accounting for ciprofloxacin resistance.Conclusions:
These are the first multiresistant S. agalactiae with the bifunctional AAC(6')-APH(2â³) enzyme to be reported in the UK for >10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin/gentamicin synergy is likely to be lost.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções Estreptocócicas
/
Streptococcus agalactiae
/
Gentamicinas
/
Bacteriemia
/
Análise de Sequência de DNA
/
Farmacorresistência Bacteriana
/
Antibacterianos
Tipo de estudo:
Screening_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article